^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ART6043

    i
    Other names: ART6043, ART-6043, ART 6043
    Associations

    News

    Trials
    Company:
    Artios Pharma
    Drug class:
    POLQ inhibitor
    Related drugs:
    Associations

    News

    Trials
    16d
    ART6043C001: Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) (clinicaltrials.gov)
    P1/2, N=181, Recruiting, Artios Pharma Ltd | Active, not recruiting --> Recruiting | Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: May 2026 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • ART6043
    7ms
    ART6043C001: Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov)
    P1/2, N=220, Active, not recruiting, Artios Pharma Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Lynparza (olaparib) • ART6043
    almost3years
    Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov)
    P1/2, N=250, Recruiting, Artios Pharma Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • ART6043
    almost3years
    Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov)
    P1/2, N=250, Not yet recruiting, Artios Pharma Ltd
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • ART6043